Structured Summary:
In patients with type 2 diabetes suffering from diabetic peripheral neuropathy (DPN),
nanocurcumin supplementation did not significantly improve pain, neuropathic outcomes, metabolic, or cardiovascular parameters compared to placebo, though it was associated with no significant adverse effects.
| PICO | Description |
|---|---|
| Population | Patients with type 2 diabetes suffering from diabetic peripheral neuropathy. |
| Intervention | Daily nanocurcumin supplementation over 16 weeks. |
| Comparison | Placebo. |
| Outcome | Over 16 weeks, nanocurcumin did not improve pain levels, neuropathy scoring, or metabolic and cardiovascular parameters compared to placebo. It was well tolerated without significant adverse effects reported. |
Source: Mansour, Asieh, et al. “The effectiveness and safety of nanocurcumin supplementation for diabetic peripheral neuropathy in patients with type 2 diabetes: a randomized double-blind clinical trial.” Read article here.
